The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| ABEO | -6.85% | -87.75% | -34.29% | -100% |
| S&P | +15.66% | +86.6% | +13.29% | +1,012% |
Abeona Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development of gene therapy for severe and life-threatening rare diseases. It programs include EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB), ABO-102 (AAV-SGSH), an adeno-associated virus (AAV) based gene therapy for Sanfilippo syndrome type A (MPS IIIA), and ABO-101 (AAV NAGLU), an AAV based gene therapy for Sanfilippo syndrome type B (MPS IIIB). The company was founded in 1974 and is headquartered in Cleveland, OH.
This company is making excellent progress on its treatment for a very rare and serious skin disorder.
| Q3 2025 | YOY Change | |
|---|---|---|
| Revenue | $0.00K | 0.0% |
| Gross Profit | -$1,376.00K | -90.6% |
| Gross Margin | -117.00% | 0.0% |
| Market Cap | $270.75M | -1.1% |
| Market Cap / Employee | $1.99M | 0.0% |
| Employees | 136 | 61.9% |
| Net Income | -$5,161.00K | 82.9% |
| EBITDA | -$23,130.00K | -58.2% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q3 2025 | YOY Change | |
|---|---|---|
| Net Cash | $83.22M | 418.1% |
| Inventory | 4.8 | 0.0% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $15.12M | -14.2% |
| Short Term Debt | $8.99M | 63.4% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Return On Assets | 46.83% | 122.9% |
| Return On Invested Capital | -146.08% | -12.9% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$23,707.00K | -87.6% |
| Operating Free Cash Flow | -$21,187.00K | -73.2% |
| Metric | Q2 2025 | Q3 2025 | YoY Change | ||
|---|---|---|---|---|---|
| Price to Earnings | 9.00 | 4.53 | - | ||
| Price to Book | 5.28 | 4.93 | 6.72 | 1.65 | -53.99% |
| Price to Sales | 36.58 | 56.58 | 946.30 | 716.00 | - |
| Price to Tangible Book Value | 5.28 | 4.93 | 6.72 | 1.65 | -53.99% |
| Enterprise Value to EBITDA | -11.28 | -9.33 | -8.02 | -4.46 | -69.97% |
| Return on Equity | -216.6% | -271.8% | 48.3% | 75.9% | -136.23% |
| Total Debt | $23.05M | $23.98M | $24.08M | $24.11M | 4.32% |
No podcast episodes available.
ABEO earnings call for the period ending June 30, 2019.
ABEO earnings call for the period ending March 31, 2019.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
